Posted by Michael Wonder on 16 May 2022
PHARMAC widens access to medicine for RSV
16 May 2022 - PHARMAC has announced today that it will be funding the preventative treatment, palivizumab, for the next two seasons of respiratory syncytial virus for young children with severe diseases who need to be ventilated and pēpi (babies) with a high susceptibility for respiratory syncytial virus related illness and complications.
Access is being widened to ensure our most vulnerable pēpi are protected, including more high risk Māori and Pacific pēpi.
